No class has yet been certified in the above action. Until aclass is certified, you are not represented by counsel unless youretain one. If you purchased Motorola common stock during the perioddescribed above, you have certain rights, and have until no later than60 days, in which to move for Lead Plaintiff status. Any member of thepurported class may move the Court to serve as lead plaintiff throughcounsel of their choice, or may choose to do nothing and remain anabsent class member.

To be a member of the class you need not take any action atthis time, and you may retain counsel of your choice. If you wish todiscuss this action or have any questions concerning this Notice oryour rights or interests with respect to these matters, please contactTali Leger, Director of Shareholder Relations at The Brualdi Law Firm,29 Broadway, Suite 2400, New York, New York 10006, by telephone tollfree at (877) 495-1877 or (212) 952-0602, by email totleger@brualdilawfirm.com or visit our website athttp://www.brualdilawfirm.com/

The complaint charges Motorola and certain of its officers anddirectors with violations of the Securities Exchange Act of 1934.Motorola builds, markets and sells products, services and applicationsthat make connections to people, information and entertainment throughbroadband, embedded systems and wireless networks.

The complaint alleges that in the summer of 2006, Motorola'spoor financial performance had depressed its stock price to below $19per share. In order to artificially inflate the price of Motorolastock, defendants began a series of false and misleading statementsregarding the Company's business and prospects. Specifically,defendants repeatedly told investors to expect strong growth in salesand revenues. On October 17, 2006, defendants announced that Motorolahad failed to meet its revenue and sales projections. As a result ofthis announcement, Motorola's stock price declined over 7% in twotrading days. Then on January 4, 2007, defendants announced thatMotorola's fourth quarter 2006 results also failed to meetexpectations. This time, the Company's stock price declined almost 8%.

CONTACT:  The Brualdi Law Firm

          Tali Leger, Director of Shareholder Relations

          (877) 495-1877

          (212) 952-0602

          tleger@brualdilawfirm.com

          http://www.brualdilawfirm.com/

The company noted that this class action lawsuit settlement will have no impact on earnings and capital in 2007, as it has accrued $74.25 million in 2005 for the potential settlement of the class action lawsuit.

Pamela Kincaid, 51, died Wednesday after friends said she fell four floors from a hospital stairwell.

The Fresno County Coroner's Office has called for an autopsy on Kincaid, who was also assaulted a few weeks before her death, said Dr. David Hadden, the county coroner. Kincaid was hospitalized after that attack with bruises on her head and abrasions on her body and face, according to police.

Kincaid was among a group of homeless people who sued the city last year for seizing and destroying their property during the raids. A federal judge granted the lawsuit class-action status Monday, which allows other homeless people who claim their personal property was taken and destroyed by the city to join the case.

In November, U.S. District Court Judge Oliver W. Wanger ordered the city to stop taking homeless people's property while the lawsuit made its way through court.

PharmaNet was formerly known as SFBC International Inc.

Under the settlement agreement, the class will be paid $28.5 million, of which $24.5 million will be in cash and $4 million may be either in cash or in stock, at the election of the company. The settlement requires contributions from a number of different defendants, and specifically requires certain of the company's former directors, officers and employees to make a personal contribution towards the settlement of the class' claims.

"We are pleased to have reached a settlement of this securities class action on terms that provide a significant benefit to the class, while permitting the company and its new management to focus on the future. We believe that the personal contribution portion of this settlement sends a clear message that shareholders will insist that the directors, officers and employees of publicly traded companies live up to their responsibilities to act as vigilant guardians for the interests of the shareholders they represent," said Paul Doane, director of ATRS.

The lawsuit, which originally was filed in 2004, had alleged the Novartis unit was discriminatory in its pay, promotions, evaluations and treatment of women who take pregnancy leave. A Novartis spokesman declined to comment, saying the company had just received the judge's order and was reviewing it.